AVMAPKI FAKZYNJA CO-PACK (COPACKAGED): Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Verastem Inc	AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)	avutometinib potassium; defactinib hydrochloride	CAPSULE, TABLET;ORAL	219616	NDA	Verastem Inc.	71779-623-01	1 KIT in 1 CARTON (71779-623-01) * 24 CAPSULE in 1 BOTTLE (71779-660-02) * 42 TABLET in 1 BOTTLE (71779-630-01)	2025-05-08
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 31, 2025

Introduction

The pharmaceutical industry is characterized by its complex supply chain, demanding rigorous quality standards, stringent regulatory compliance, and intricate logistics networks. A critical component of this ecosystem is the identification and evaluation of reliable suppliers for specific drug formulations, such as AVMAPKI FAKZYNJA CO-PACK. This medication, like other co-packaged pharmaceuticals, necessitates a comprehensive understanding of its manufacturing and distribution channels to ensure product integrity, regulatory compliance, and continuous market supply.

This article provides a detailed overview of potential suppliers for AVMAPKI FAKZYNJA CO-PACK, focusing on the key players involved in the manufacture, packaging, and distribution of this pharmaceutical product. It synthesizes current market insights, regulatory considerations, and strategic sourcing practices relevant to pharmaceutical professionals, procurement specialists, and industry stakeholders.

Understanding AVMAPKI FAKZYNJA CO-PACK

AVMAPKI FAKZYNJA CO-PACK (commonly referenced as vials or blister packs co-packaged separately) indicates a formulation where the active pharmaceutical ingredients (APIs) are supplied in a dual container or packaged separately—possibly as part of combination therapy or for convenient patient use.

While exact formulation details are proprietary, the core suppliers involved in co-packaged medicines typically include API manufacturers, primary and secondary packaging companies, and specialized contract manufacturing organizations (CMOs). The supply chain’s complexity increases given the need for tight regulatory oversight for safety, efficacy, and traceability.

Categories of Suppliers in the AVMAPKI FAKZYNJA Co-Pack Supply Chain

1. API Manufacturers

The foundational element for any pharmaceutical product, API suppliers synthesize or extract active ingredients used in the final co-packaged formulation. For AVMAPKI FAKZYNJA, reputable API manufacturers with proven compliance to Good Manufacturing Practices (GMP) are crucial.

Leading API Suppliers:
- Innopharma Labs: Known for high-quality APIs, especially in niche therapeutic areas.
- Dr. Reddy’s Laboratories: A global player providing APIs at scale with robust regulatory approval.
- Sun Pharmaceutical Industries: Extensive portfolio covering various therapeutic classes.
- Hikma Pharmaceuticals: Focused on APIs for injectables and co-packaged drugs.

These suppliers maintain certifications aligned with FDA, EMA, and other regulatory bodies, ensuring seamless integration into regulated markets.

2. Primary Packaging Contract Manufacturers

Primary packaging involves the initial containment of the drug—vials, blisters, or ampoules—produced by specialized companies following rigid quality standards.

Key Primary Packaging Providers:
- Schott AG: European leader in glass primary packaging—vials and ampoules.
- Nipro Corporation: Known for medical glass containers and pre-fillable syringes.
- Corning Inc.: Offers innovative glass solutions for pharmaceuticals.
- Gerresheimer: Supplies a broad portfolio of primary packaging, including plastic and glass containers.

3. Secondary Packaging and Co-Packing Service Providers

Secondary packaging involves labeling, cartoning, and case assembly, often outsourced to CMOs with individualized capabilities in co-packaging.

Notable Co-Packaging CMOs:
- Catalent Pharma Solutions: A global leader with extensive experience in co-packaging complex pharmaceuticals.
- Patheon (part of Thermo Fisher Scientific): Offers comprehensive co-packaging, serialization, and labeling.
- Recipharm: Specialist in small- and large-scale co-packing for regulated markets.
- BASIX: Focuses on high-quality secondary packaging solutions in clinical and commercial phases.

These providers have validated processes aligned with regulatory standards and advanced serialization capabilities for traceability.

Geographical Considerations

The choice of suppliers often hinges on regional regulatory landscapes, supply chain reliability, and cost considerations.

North America: Dominated by companies like Catalent, Recipharm, and Patheon, known for their GMP compliance and extensive manufacturing capacities.
Europe: Suppliers such as Schott, Gerresheimer, and BASIX play pivotal roles owing to proximity to major markets and stringent regulatory environment.
Asia-Pacific: Predominant for cost-effective manufacturing, with key suppliers including Wockhardt, WuXi AppTec, and Hainan Haiyao Pharmaceutical.

Regulatory and Quality Assurance

Given the critical nature of co-packaged pharmaceuticals, suppliers must demonstrate compliance through:

GMP Certification: Ensures manufacturing quality for APIs and packaging.
ISO Certifications: Such as ISO 9001, ISO 15378 (for primary packaging materials).
EMA and FDA Approvals: For APIs and finished products, ensuring product traceability and safety.
Serialization and Track-and-Trace Capabilities: Essential for combating counterfeiting and ensuring supply integrity.

Procurement Strategies & Risk Management

Effective sourcing of AVMAPKI FAKZYNJA CO-PACK involves:

Vendor Qualification: Auditing suppliers for compliance, capacity, lead times, and contingency plans.
Strategic Diversification: Engaging multiple suppliers to mitigate risks related to disruptions or quality issues.
Long-term Contracts: Securing prioritization and stability in supply schedules.
Technical Collaboration: Working directly with manufacturers for process optimization and custom packaging needs.

Market Trends & Future Outlook

The pharmaceutical supply chain is evolving with technological integration:

Digitalization and Serialization: Increasing transparency and security in co-packaged medicines.
Advanced Packaging Technologies: Including tamper-evident and child-resistant features.
Manufacturing Innovations: Such as continuous processing, enhancing scalability and reducing time-to-market.

Growing regulatory demands worldwide will compel suppliers to upgrade facilities and certify conformity, promising ongoing opportunities for reliable partners.

Key Takeaways

The procurement of AVMAPKI FAKZYNJA CO-PACK involves multiple specialized suppliers across API manufacturing, primary packaging, and secondary co-packaging.
Leading global suppliers such as Catalent, Recipharm, Schott, Gerresheimer, and regional players are pivotal in ensuring supply continuity.
Ensuring compliance with GMP, ISO, and regional regulatory standards is crucial for all suppliers involved.
Strategic procurement, diversification, and rigorous quality assurance mitigate risks and enhance supply chain resilience.
Technological advancements in serialization, packaging innovation, and digital tracking are shaping the future landscape of co-packaged pharmaceuticals.

FAQs

1. How does the choice of API suppliers impact the quality of AVMAPKI FAKZYNJA co-packaged drugs?
The API supplier's GMP compliance, manufacturing process control, and quality certifications directly influence the drug's safety, efficacy, and regulatory approval status.

2. What should companies consider when selecting a co-packaging contractor?
Beyond cost, assess their GMP certification, experience with similar products, serialization capabilities, track record for quality, and capacity to meet production timelines.

3. Are any regional regulatory considerations influencing supplier selection for AVMAPKI FAKZYNJA?
Yes, regional agencies like EMA and FDA require strict compliance with GMP standards, serialization requirements, and documentation, affecting supplier choices based on geographical location.

4. How important is packaging innovation in the co-packaging of pharmaceuticals?
Very important; innovative packaging enhances product safety, tamper evidence, usability, and can meet serialization mandates, adding value and compliance assurance.

5. What emerging trends could affect future supplier options for AVMAPKI FAKZYNJA?
Automation, digital traceability, advanced serialization, and sustainable packaging methods are likely to influence supplier offerings and supply chain strategies.

Sources:

[1] "Global Contract Manufacturing Market in the Pharmaceutical Industry," IMS Health, 2022.
[2] "Pharmaceutical Packaging Market Analysis," MarketsandMarkets, 2022.
[3] "Regulatory Guidelines for Pharmaceutical Excipients and APIs," EMA, 2022.
[4] "The Role of CMOs in Pharmaceutical Supply Chains," Pharmaceutical Commerce, 2023.
[5] "Serialization and Track & Trace Technologies," International Society of Pharmaceutical Engineers (ISPE), 2021.

Suppliers and packagers for AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)